The innovative drug sector is experiencing multiple positive signals! Several core targets reveal the latest business developments.

Last week (from March 30 to April 3), after a modest rebound, the broader market fell again. The Shanghai Composite Index dropped 0.86% for the week, falling below the 3,900 level. The Shenzhen Component Index fell 2.96%, and the ChiNext Index fell 4.44%.

In terms of sectors, a small number of sectors such as pharmaceuticals and biotech, communications, and food and beverage stayed in positive territory, while power, real estate, coal, and chemical sectors saw sharp pullbacks. In concept sectors, innovations drugs, the CPO concept, and cross-border payments strengthened against the trend.

With increased medical insurance volume, outbound BD surging, confirmation of an earnings inflection point, and, on top of that, funds returning from low levels, under the combined effect of multiple factors, the innovations drugs sector led the market higher last week against the trend.

Multiple brokerages noted that the innovations drugs sector is currently in a favorable stage characterized by “earnings delivery, valuation repair, and meeting catalysts,” and that the industry chain is entering a period of value realization.

According to incomplete statistics, last week several listed companies responded on investor interaction platforms to questions related to innovations drugs:

On Friday last week, Yangguang Nuoer disclosed on an investor interaction platform that the company’s wholly owned subsidiary, Chengdu Novo Shengtai, using solid-phase synthesis technology, can already stably synthesize drugs such as semaglutide and tirzepatide, and can carry out in-depth research based on market conditions and the company’s business layout. “The company performs multiple GLP-1 class innovative drug clinical trial services, covering weight loss and blood-sugar-lowering indications, which are at clinical phases I to III, respectively.”

Innovations drugs giant Hengrui Pharmaceutical stated that, currently, the company has 24 Type 1 innovative drugs and 5 Type 2 new drugs approved for listing in China, and more than 100 independently innovative products are under clinical development, with more than 400 clinical trials conducted domestically and overseas. In 2025 alone, the company completed five overseas business expansion transactions, and confirmed external licensing revenue of 3,392 million yuan. Since 2023, the company has completed 12 overseas business expansion transactions, including different models such as external licensing, NewCo, and strategic alliances, with a potential total transaction value exceeding $27 billion.

Zixiang Jintai revealed that, as of now, two indications for its cerci lizumab injection have already been included in the National Reimbursement Drug List. New drug listing applications for slevemab vedolizumab injection, Viconduotaximab injection, and talice bisimab injection have been accepted by the National Medical Products Administration, and conditional listing applications for weili tumab injection have also been accepted. Multiple of the company’s products are in clinical trial stages, and at the same time, it is focused on building two new technology platforms in order to launch more innovative products.

On Wednesday of last week, Giber said that currently, its R&D pipeline mainly includes an anti-depression class new drug, JJH201501; an anti-tumor class new drug, JJH201601; an anti-gastric-acid class new drug, JJH201701; an anti-cholecystitis and gallstones class new drug, JJH201801; glucose-lowering new drug—sanconi sulfonamide capsules; an anesthetic and analgesic new drug; and various combination glucose-lowering new drugs. Among them, the anti-depression class new drug JJH201501 has completed Phase III clinical trials; the anti-tumor class new drug JJH201601 is conducting Phase IIa clinical trials.

(Source: Eastmoney Research Center)